CLDX CELLDEX THERAPEUTICS INC Operational Disruptions 8-K Filing 2023 - Positive Clinical Data Announcement Celldex Therapeutics announced positive topline data from their Phase 2 study of barzolvolimab in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines, supporting further development in Phase 3 studies.Get access to all SEC 8-K filings of the CELLDEX THERAPEUTICS INC